Likewise, AZD2858, a Gsk3 inhibitor, significantly increases the bone mass in rats by upregulating the β-catenin levels (Marsell et al. 2012), further validating this inhibitor in the osteoporosis therapy by targeting the ROCK/JAK/GSK3β signaling. The gene discussed is GSK3B; the disease is osteoporosis.